anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

11 Golden Circle

Loop collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 13,983
Current window 8,821-8,850
Pages 467
Rows per page 30
Loop: 11 Golden Circleclear collectionreset all
18 30 60

Loop

8,821-8,850 of 13,983

filter-aware
06
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
07
The slide uses a split-layout: left side describes the drug product, right side lists clinical trial status for Fibromyalgia, Long COVID, and PTSD.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
Includes clinical trial status (RELIEF, RALLY, RESILIENT) and market demographics.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
Clinical trial design slide for Tonix Pharmaceuticals.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
Slide 10 of a corporate presentation deck.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide outlines a clinical trial protocol for TNX-102 SL in Long COVID patients.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
12
Includes disclaimer about non-approval and patent status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
Slide 13 of a Tonix Pharmaceuticals presentation.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
Includes clinical trial status and mechanism of action highlights.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Slide provides a high-level summary of a pharmaceutical asset's profile and development roadmap.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
17
The slide uses a two-column layout to contrast the disease profile with the development program status.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
19
Includes a comparison of three generations of CD40L antibodies and a structural diagram of the antibody.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
20
The slide outlines a drug development asset in the immunology portfolio.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
21
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
22
The slide uses a split-layout design with a left-hand column for platform differentiators and a right-hand column for specific product status and next steps.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
23
The slide uses a process-like diagram to show the evolution from historical vaccines (Vaccinia, Horsepox) to a modern programmable 'Antigen Coding' platform.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
24
The slide lists three distinct facilities: RDC (Frederick, MD), ADC (North Dartmouth, MA), and CMC (Hamilton, MT).Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
25
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
26
The slide uses checkmarks for completed items and empty squares for future items.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
27
The slide uses a grid-like layout to associate logos of institutions with specific TNX drug candidates.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
28
Tonix Pharmaceuticals | Investor Presentation Deck | 29 slidesTonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Beat · TeamLoop · Golden Circle1 hit
29
Standard corporate closing slide.Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides · Tonix Pharmaceuticals
Conference presentation Investor relations Loop · Golden Circle1 hit
05
Xeris Biopharma | Investor Presentation Deck | 11 slidesXeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
06
The slide outlines a clinical trial structure involving two parts, with crossover periods for Part 1.Xeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
07
The chart compares subcutaneous (SC) administration of XP-8121 against oral (PO) administration of Synthroid.Xeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
Clinical trial data (XP-8121-108) comparing subcutaneous (SC) vs oral (PO) administration.Xeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The chart shows a comparison of simulated thyroxine concentrations over 7 days.Xeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Loop · Golden Circle1 hit
10
Xeris Biopharma | Investor Presentation Deck | 11 slidesXeris Biopharma | Investor Presentation Deck | 11 slides · Xeris Biopharma
Pitch deck Investor relations Beat · Key TakeawaysLoop · Golden Circle1 hit